29 Jun Takenaka Partners Advises Yamada Bee on its Minority Investment in Healthcare Technology Startup, AHNP Precision Health
Takenaka Partners LLC (Los Angeles, CA) acted as the exclusive financial advisor for Yamada Bee Farm Inc.’s minority investment into AHNP Precision Health, LLC (AHNP), a healthcare technology company focused on preventing Alzheimer’s and dementia. Takenaka Partners worked closely with Yamada Bee to identify, conduct due diligence on, and negotiate the investment with AHNP.
AHNP, in partnership with one of the industry’s leading experts on Alzheimer’s disease and dementia, Dr. Dale Bredesen, aims to help people prevent, track, and even improve their Alzheimer’s and dementia symptoms.
AHNP achieves this by utilizing the Bredesen Protocol, a proprietary method of analyzing a participant’s genetic information, lifestyle, and other important health indicators. A personalized plan is then created that helps participants achieve lifestyle and nutritional improvements to help reduce the likelihood of developing symptoms or to lessen existing symptoms.
Yamada Bee is expanding its focus on healthcare programs and hopes to utilize and bring AHNP’s proprietary technology to the Japanese market, where over 4.6 million people are living with dementia. By combining its resources and commercial reach with AHNP’s and Dr. Bredesen’s technological and medical innovations, Yamada Bee plans to improve the lives of millions who suffer from Alzheimer’s and dementia. According to Yukuo Takenaka, President of Takenaka Partners, “Takenaka Partners is pleased to have helped facilitate Yamada Bee’s investment into such a technologically innovative and impactful company. Takenaka Partners is pleased to have been able to help structure a successful deal between the two companies.”